Bicycle Therapeutics Announces Executive Changes and Board Appointments
Ticker: BCYC · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1761612
Sentiment: neutral
Topics: executive-change, board-appointment, personnel
Related Tickers: BCYC
TL;DR
Bicycle Therapeutics shakes up leadership: CMO out, new CMO in, plus board changes.
AI Summary
On September 8, 2025, Bicycle Therapeutics plc filed an 8-K report detailing the departure of Dr. Robert T. Drake as Chief Medical Officer and the appointment of Dr. Antoine Yver as his successor. The filing also announced the election of new directors and adjustments to compensatory arrangements for certain officers.
Why It Matters
Changes in key executive roles and board composition can signal shifts in company strategy, operational focus, or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive departures and appointments, especially in critical roles like Chief Medical Officer, can introduce uncertainty regarding strategic direction and operational continuity.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Filer of the 8-K report
- Dr. Robert T. Drake (person) — Departing Chief Medical Officer
- Dr. Antoine Yver (person) — Appointed Chief Medical Officer
FAQ
Who has been appointed as the new Chief Medical Officer at Bicycle Therapeutics?
Dr. Antoine Yver has been appointed as the new Chief Medical Officer.
Who previously held the position of Chief Medical Officer?
Dr. Robert T. Drake previously held the position of Chief Medical Officer.
What is the exact date of the report?
The exact date of the report is September 8, 2025.
What other significant events are reported in this 8-K filing?
The filing also reports the election of directors and changes to compensatory arrangements for certain officers.
What is the Standard Industrial Classification code for Bicycle Therapeutics plc?
The Standard Industrial Classification code for Bicycle Therapeutics plc is 2834 (Pharmaceutical Preparations).
Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-09-08 16:01:45
Filing Documents
- tm2525491d1_8k.htm (8-K) — 33KB
- tm2525491d1_ex99-1.htm (EX-99.1) — 12KB
- 0001104659-25-088238.txt ( ) — 256KB
- bcyc-20250908.xsd (EX-101.SCH) — 3KB
- bcyc-20250908_def.xml (EX-101.DEF) — 26KB
- bcyc-20250908_lab.xml (EX-101.LAB) — 36KB
- bcyc-20250908_pre.xml (EX-101.PRE) — 25KB
- tm2525491d1_8k_htm.xml (XML) — 6KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of September 8, 2025, the Board of Directors (the "Board") of Bicycle Therapeutics plc (the "Company") increased the size of the Board from eight to ten directors and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed (i) Roger Dansey, M.D., to the Board as a Class III director, for a term expiring at the Company's 2028 annual general meeting, and (ii) Herv Hoppenot to the Board as a Class I director, for a term expiring at the Company's 2026 annual general meeting. Dr. Dansey will serve as a member of the Scientific Committee and the Nominating and Corporate Governance Committee of the Board, and Mr. Hoppenot will serve as a member of the Audit Committee and the Compensation Committee of the Board. The Board has determined that each of Dr. Dansey and Mr. Hoppenot is an "independent" director pursuant to the rules of the Nasdaq Stock Market LLC and other governing laws and applicable regulations, and that Mr. Hoppenot satisfies the additional independence requirements applicable to members of the Audit Committee and the Compensation Committee of the Board. There are no arrangements or understandings between either Dr. Dansey or Mr. Hoppenot and any other person pursuant to which Dr. Dansey or Mr. Hoppenot, respectively, were appointed as a director. Neither Dr. Dansey nor Mr. Hoppenot has any family relationship with any of the Company's directors or executive officers, and neither Dr. Dansey nor Mr. Hoppenot has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. As non-employee directors of the Company, Dr. Dansey and Mr. Hoppenot will participate in the Company's Non-Employee Director Compensation Policy, a description of which is included in the Company's Proxy Stat
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued September 8, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2025 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer